Compare Recursion Pharmaceuticals Inc (RXRX) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Airlines Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while United Airlines Holdings Inc trades at $105.7 (market cap $34.87B). The key difference: United Airlines Holdings Inc is far larger — about 16.3× Recursion Pharmaceuticals Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and United Airlines Holdings Inc for 46 Days on average.
| RXRX | UAL | |
|---|---|---|
Market Cap | $2.14B | $34.87B |
Volume | 30,789,535 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $6.79 | $136.11 |
52-Week Low | $2.84 | $85.21 |
Typical Hold Time | 22 Days | 46 Days |
Enterprise Value | $1.66B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
United Airlines (UAL) trades at $110.17, down 1.53% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.06, net income margin of 5.56%, and three consecutive quarterly EPS beats. Recent news highlights aggressive customer acquisition tactics targeting Delta's elite travelers with status-match offers and Starlink WiFi advantages.
Outlook remains positive given analyst consensus of $158.10 price target and 66% buy ratings, but risks include rising fuel costs, labor expenses, and competitive pressures. Earnings growth and market share gains are key catalysts, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
